Oklahoma City, OKNCT07183319Now EnrollingIRB Ready

Urothelial Carcinoma Clinical Trial in Oklahoma City, OK

Access cutting-edge urothelial carcinoma treatment through this phase 2 clinical trial at a research site in Oklahoma City. Study-provided care at no cost to qualified participants.

Sponsored by University of Oklahoma

Quick Self-Assessment

See if you qualify for this Oklahoma City location

Preparing your pre-screening questions…

Expert Care in Oklahoma City

Access urothelial carcinoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related urothelial carcinoma treatment provided free

Apply for This Oklahoma City Location

Check if you qualify for this urothelial carcinoma clinical trial in Oklahoma City, OK

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Oklahoma City

    Convenient for OK residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Oklahoma City site if eligible
  4. 4Begin participation

About This Urothelial Carcinoma Study in Oklahoma City

The purpose of this clinical trial is to evaluate the effectiveness of pembrolizumab monotherapy following 24 weeks of frontline pembrolizumab \& Enfortumab Vedotin (PEV) in patients with metastatic urothelial cancer (mUC).

Sponsor: University of Oklahoma

Who Can Participate

Inclusion Criteria

Have histologically documented unresectable, locally advanced, or metastatic urothelial carcinoma.
Measurable disease according to the New Response Evaluation Criteria in Solid Tumors (RECIST v1.1)38 a. Participants with prior definitive radiation therapy must have measurable disease per RECIST v1.1 that is outside the radiation field or has demonstrated unequivocal progression since completion of radiation therapy.
Must be considered eligible to receive cisplatin- or carboplatin-containing chemotherapy, in the investigator's judgment.
Archival tumor tissue comprising muscle-invasive urothelial carcinoma, or a biopsy of metastatic urothelial carcinoma must be available for tumor-informed ctDNA analysis.
Meets Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1, or 2.
Adequate hematologic and organ function (Hb ≥ 8.0 g/dL; ANC ≥ 1.5x109 cells/L; CrCl \~30 mL/min; total bilirubin ≤ 1.5 mg/dL; ALT and AST within normal limits).

Exclusion Criteria

Previously received enfortumab, vedotin, or other monomethyl auristatin E (MMAE)-based ADCs.
Received prior treatment with a programmed cell death ligand-1 (PD-(L)-1) inhibitor for any malignancy, including earlier stage UC, defined as a PD-1 inhibitor or PD-L1 inhibitor within 12 months.
Has received anti-cancer treatment with chemotherapy, biologics, or investigational agents not otherwise prohibited by exclusion criterion 1-3 that is not completed within 28 days prior to cycle 1 day 1.
Has uncontrolled diabetes or ≥ grade III peripheral neuropathy.
Patient's estimated life expectancy is less than 12 weeks.
Has untreated central nervous system metastases.
Experiences ongoing clinically significant toxicity associated with prior treatment that has not resolved to ≤ Grade 1 or returned to baseline.
Is currently receiving systemic antimicrobial treatment for active infection (viral, bacterial, or fungal). Routine antimicrobial prophylaxis is permitted.
Has known active hepatitis B, active hepatitis C, or human immunodeficiency virus (HIV) infection.
Has history of another invasive malignancy requiring treatment within 3 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy (excluding localized prostate cancer or basal cell carcinoma of skin or squamous cell carcinoma of the skin).
Has documented history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction, or cardiac symptoms consistent with New York Heart Association (NYHA) Class IV within 6 months.
Received radiotherapy within 2 weeks.
Received major surgery (defined as requiring general anesthesia and \>24-hour inpatient hospitalization) within 2 weeks.
Known severe (≥ Grade 3) hypersensitivity to any EV excipient contained in the drug formulation of EV.
Has active keratitis or corneal ulcerations.
Has a history of autoimmune disease that has required systemic immunosupressive treatment in the past 2 years, or uncontrolled autoimmune disease.
Participants must not have received prior systemic therapy for locally advanced or metastatic urothelial carcinoma with the following exceptions:
Participants that received neoadjuvant chemotherapy with recurrence \>12 months from completion of therapy are permitted.
Participants that received adjuvant chemotherapy or ICPIs therapy following cystectomy with recurrence \>12 months from completion of therapy are permitted.
Has a history of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan.
Has received prior allogeneic stem cell or solid organ transplant.
Received a live attenuated vaccine within 30 days.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Oklahoma City?

Yes, this clinical trial (NCT07183319) has an active research site in Oklahoma City, OK that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Urothelial Carcinoma Treatment Options in Oklahoma City, OK

If you're searching for urothelial carcinoma treatment options in Oklahoma City, OK, this clinical trial (NCT07183319) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Oklahoma City research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced urothelial carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all urothelial carcinoma clinical trials near you to find additional studies recruiting in your area.

More Bladder Cancer Trials in Oklahoma City, OK

See all bladder cancer clinical trials recruiting in Oklahoma City — not just this study.

Browse Bladder Cancer Trials in Oklahoma City →

Browse More Trials by Condition

Bladder Cancer TrialsAll Conditions →

Ready to Join in Oklahoma City?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Oklahoma City, OK